An investor who built a multimillion-dollar real estate portfolio by buying 'pigs' explains how he finds overlooked properties
He's scaled to more than 30 properties that bring in seven figures in annual rental income.
Barker's strategy involves finding and buying overlooked properties.
Jeremy Barker stumbled into real estate investing when his startup outgrew its original space, prompting him to look into large commercial properties.
He bought a bigger space than he needed, leased nearly 80% of it to tenants, and started generating rental income from his new headquarters. What's more, he said the building has more than quadrupled in value within the past decade.
From there, "I just rinsed and repeated," Barker told Business Insider.
The entrepreneur, who started his business Murphy Door to supplement his $1,600 a month firefighter paycheck, has grown to more than 30 commercial and residential properties that generate seven figures in annual rental income. BI confirmed his property ownership by reviewing his 2024 property tax notices and lease agreements between him and his tenants.
One key to his real estate strategy is buying overlooked properties. That's how he scores deals and, ultimately, sees millions of dollars in appreciation.
Barker is looking at buildings that most people aren't.
"I like to look for pigs," he said — meaning, something that's dilapidated or doesn't look nice, but has potential. "We could put lipstick on it and make it look really pretty."
For example, while driving through his market in Utah, he noticed a 90,000-square-foot call center right off the highway. The old office space, which was still littered with desks, chairs, and servers, had been empty for a couple of years.
"The property is just dilapidated," he recalled. "The outside's ugly, the landscape's overgrown, the trees are too big, the inside looks really overwhelming because it's a lot of square footage with a lot of stuff."
While most investors wouldn't even do a walkthrough, Barker saw an opportunity.
"Coming from a construction background, I'm like, I could cut down the big trees, get the yard cleaned up, paint the exterior for cheap, put new LED on the outside, gut all the cubicles, sell those for some kind of money, and then I can do new flooring," he said.
He knew he had leverage, since the building had been sitting on the market for years. It was listed for about $3.4 million, and Barker said he initially offered $2 million: "It came back to $2.9 million, and then I found about $500,000 or $600,000 worth of deferred maintenance issues that they credited me at close, so I ended up buying this for $2.4 million."
Before closing, he put a "for lease" sign up outside the building and landed his first tenants before even putting any money down. Within 12 months of purchasing the property, it was fully leased.
Barker isn't just looking for dilapidated buildings that have potential. He has specific location criteria.
"I tell my realtor, 'Find me something that is in a good spot. It doesn't have to be the best spot. It just has to have some lower vacancy rates in the area. It has to be pretty accessible to business, so good highways next to it.'"
Barker has two tried-and-true strategies that help him land deals.
"First and foremost, the secret is: How long has it been on the market? How desperate are these guys?" he said. "The long market tells are important to me."
Chances are, he'll have more negotiating power on a building that's been vacant for more than a year than one that just came on the market.
Next, he's looking for companies that are moving out of their office space.
"This is kind of my secret recipe: If I can find companies that are selling their main office. Usually, it's single-tenant occupants held by the corporation that are now moving to a different headquarters."
This type of seller is usually not looking to lease the space — they just want to sell, explained Barker: "If you can find a single company that's leaving, they put it for sale only and it sits there for four or five years because everybody sees the building for sale, but it never says 'for lease.' Most people aren't going to buy the whole big building."
That's where he'll come in, sign a purchase and sale agreement that allows him to immediately put up a 'for lease' sign before closing, and "all of a sudden, your phone starts blowing up," he said. "So if you can get it to where you're the future lessor, and you get the calls when the sign transfers from 'for sale' to 'for lease,' now you can see demand."
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on Valueinvesting subreddit by bluespacecolombo. In this article, we will summarize the bulls' thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at $27.61 as of July 28th. A scientist in a laboratory coat looking into a microscope at human bone regeneration samples. Ultragenyx Pharmaceutical (RARE) has seen its share price halve in just two weeks, largely due to a halted trial and an FDA rejection, but the market appears to have overreacted. The company's Phase 3 trial for setrusumab, a potential blockbuster therapy for a rare bone disease, failed to meet an early 'stop-for-efficacy' milestone, yet the study remains on track, with safety intact and final results expected in late 2025 under less stringent endpoints. Meanwhile, the FDA issued a complete response letter for another gene therapy candidate, citing manufacturing issues rather than safety or efficacy concerns. The program remains viable, with a resubmission expected once production adjustments are made. Despite these setbacks, Ultragenyx continues to generate meaningful revenue, posting $139 million in Q1 and guiding for over $640 million in 2025, and maintains a robust cash position of around $560 million, with management projecting lower cash burn. Beyond setrusumab, the company's pipeline is well diversified, featuring DTX401, a gene therapy for glycogen storage disease that met Phase 3 goals and is slated for FDA submission this year, as well as an advanced Angelman syndrome program in Phase 3. None of the recent regulatory or clinical updates involved failures of safety or efficacy, leaving the scientific foundation of the pipeline intact. Analysts' average price targets remain near $100, implying a potential threefold upside from the current ~$26 level. With solid fundamentals, multiple near-term catalysts, and a temporarily depressed valuation, Ultragenyx represents a compelling contrarian opportunity as panic-driven selling unwinds. Previously we covered a bullish thesis on Capricor Therapeutics, Inc. (CAPR) by androidmj in March 2025, which highlighted the upcoming FDA decision on Deramiocel, strong financial backing, and significant upside on approval. The company's stock has depreciated about 46.32% since then as the thesis has yet to play out. The thesis still stands given CAPR's cash runway and de-risked catalyst. bluespacecolombo shares a similar view on the biotech space but emphasizes Ultragenyx's diversified pipeline, overreaction-driven selloff, and near-term catalysts. Ultragenyx Pharmaceutical Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 55 hedge fund portfolios held RARE at the end of the first quarter which was 57 in the previous quarter. While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24 minutes ago
- Yahoo
Tesla Offers Musk $30 Billion to Stay--With Strings Attached
Tesla (NASDAQ:TSLA) just handed CEO Elon Musk a massive new stock awardworth around $30 billiondesigned to keep him anchored at the helm while the company weathers legal battles and business headwinds. The package includes 96 million shares at a $23.34 exercise price, and it only kicks in if Musk stays in a senior leadership role for another two years. It's a stopgap move while the board appeals a court decision that voided his original 2018 compensation plan. That plan, once pegged at $56 billion, has become a flashpoint for investors and governance advocates alike. The interim award signals Tesla's intent to keep Musk focused during a volatile phase for the business. Tesla's board calls this a good faith gestureand timing matters. After a tough first half marked by declining sales, falling revenue, and a 25% YTD drop in share price, the company is leaning heavily on Musk's leadership to navigate what it describes as a critical inflection point. According to Wedbush analyst Dan Ives, the new agreement helps remove a lingering cloud over the stock and likely cements Musk's role for the foreseeable future. The board is also developing a longer-term pay structure, to be voted on at the November 6 shareholder meeting. But leadership retention isn't the only thing on the line. Musk's attention has been split across multiple venturesSpaceX, xAI, X Corp, Neuralink, The Boring Companyand his recent political entanglements haven't helped. The board acknowledges these distractions but says Musk remains central to Tesla's ability to attract and retain talent. Meanwhile, Tesla is trying to build momentum around its new robotaxi program, launched in Austin, which could be a long-term growth lever. Whether this compensation reset keeps Musk focused on Teslaor just buys timeis what investors will be watching next. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
How to get free Burger King Whoppers for 6 days straight
Burger King and Walmart+ lovers to the front. The companies are offering a deal that'll give customers a free Whopper with a $1 purchase for six days straight. The deal is only available for shoppers who are members of both Walmart+ and Burger King Royal Perks programs, a Burger King representative told USA TODAY via email. The deal will run from Tuesday, Aug. 5, to Monday, Aug. 11. The special was announced to celebrate the one-year anniversary of Walmart and Burger King's first-ever joint promotion, launched last summer. Last year's deal gave Walmart+ members 25% off any Burger King digital order every day, as well as a free Whopper every three months starting in September 2024. Here's what to know to get the deal: Read more: Walmart+ members get 25% off Burger King, free Whoppers in new partnership How can I get my free Whopper this week? Guests can take advantage of the deal by linking their Burger King Royal Perks and Walmart+ accounts. To link your accounts: Make sure the Burger King app is downloaded on your device. Download the Walmart app and sign in. Or, log in at Go to "Account." Select "Walmart+ membership." Find the Burger King Savings benefit and select "Get started." The Burger King app should open automatically. Select the "Link accounts" button. Once customers have linked their Walmart+ and Burger King accounts, they can redeem the offer by: ordering in-store using their 6-digit code, opening the Burger King app, going to the 'Offers' tab and activating the offer, and logging in at to place an order. Did someone say diner? Elon Musk fans flock to new Tesla Diner Are there any restrictions? The deal is not available during breakfast hours except at select locations, and customers can only get one free Whopper per account each day, Burger King said. The offer cannot be used with delivery orders. More on Walmart+ and Burger King Royal Perks Walmart+ is Walmart's delivery program that starts at $12.95 a month or $98 annually. The program has student and government assistance eligibility, per the company's website. Royal Parks is Burger King's free rewards program that allows customers to earn points, or crowns, for every $1 spent on eligible transactions. Customers can then cash in the crowns for free menu items. Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@ This article originally appeared on USA TODAY: Got Walmart+ and Burger King Royal Perks? Get a free Whopper.